Centricity Research

Running trials

• Active, not recruiting

  A Study to Identify an Optimal Dose of QCZ484 in Mild to Moderate Hypertensive Patients

  NCT06857955· Phase 2· Source

• Active, not recruiting

  CONtiNuous glucosE Monitoring (CGM) in People wiTh Type 2 Diabetes Not on Insulin

  NCT06601166· Source

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  NE3107 in Adults With Neurological Symptoms of Long COVID

  NCT06847191· Phase 2· Source

• Completed

  Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2)

  NCT06926842· Phase 2· Source

• Completed

  A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Lower Blood Sugar in People With Type 2 Diabetes

  NCT06326047· Phase 2· Source

• Completed

  Intratumoral PH-762 for Cutaneous Carcinoma

  NCT06014086· Phase 1· Source

• Completed

  A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor

  NCT06065540· Phase 3· Source

• Withdrawn

  A Study of BMN 255 in Participants With Non-Alcoholic Fatty Liver Disease And Hyperoxaluria

  NCT06138327· Phase 1· Source

• Completed

  Study of DISC-0974 to Assess the Safety, Tolerability, PK and PD of DISC-0974 in Participants With CKD and Anemia

  NCT05745883· Phase 1· Source

• Completed

  Study to Evaluate the Efficacy and Safety of K-877-ER and CSG452 in Participants With NASH With Liver Fibrosis

  NCT05327127· Phase 2· Source

• Completed

  A Comparison of PT027 vs PT007 Used as Needed in Participants With Asthma

  NCT05505734· Phase 3· Source

• Completed

  Randomized Study to Evaluate the Effect of Obicetrapib on Top of Maximum Tolerated Lipid-Modifying Therapies

  NCT05142722· Phase 3· Source